PHILADELPHIA (StudyFinds.org– According to recent research, hospital superbugs can be killed by a new antibiotic. The new drugs have been described as a “potential turning point” in the fight against drug resistance (AMR). This is the first discovery of its kind in more than three decades.
The World Health Organization (WHO) has declared AMR as one of the 10 global public health threats against humanity. It is estimated that by 2050, antibiotic-resistant infections could claim the lives of 10 million people a year, costing the global economy more than $103 trillion.
These new drugs work against a wide range of bacteria by activating the adaptive immune system: molecules that essentially mutate in response, researchers from The Wistar Institute of Anatomy and Biology say. with invasive bugs, such as methicillin-resistant Staphylococcus aureus (MRSA) and clostridium difficile (C other).
“We have implemented an innovative dual strategy to develop novel molecules that can kill difficult-to-treat infections while enhancing the host’s natural immune response,” said lead author of the study. study, explains Dr Farokh Dotiwala of the Center for Vaccines & Immunity at Wistar, in a statement.
Golden period antibiotic discovery was in the 1950s and 1960s. The last to get into the hands of doctors dates back to 1987. Since then, bacteria have become very resistant to drugs. So the team at the Wistar Institute focused on a metabolic pathway that is essential for most bacteria, but not in humans.
The road, called methylerythritol phosphate (MEP), is responsible for the biosynthesis of isoprenoids, or molecules required for cell survival in most pathogenic bacteria. The lab targeted an essential enzyme in this process called IspH. It blocks chemicals and kills bacteria.
Given its widespread presence, the method has implications for the entire microbial world. The new generation of antibacterial has been named dual action immune antibiotic (DAIA).
Resistance is achieved by modifying the target bacteria the antibiotic is targeting, inactivating the drug, or pumping it out. “We reasoned that mining Immune System Dr Dotiwala explains that attacking bacteria on two different fronts simultaneously makes it difficult for them to develop resistance.
List of bacteria are becoming resistant to treatment with all the antibiotic options available are growing. Very few new drugs are being produced, creating an urgent need for new antibiotics to avert public health crises. The researchers used computer modeling to screen millions of commercially available compounds for their ability to bind to enzymes. The strongest points were selected as starting points.
Dr Dotiwala and co-author of the study, Professor Joseph Salvino of the Wistar Cancer Center, have identified and synthesized novel IspH-inhibiting molecules that can penetrate inside bacteria. In laboratory tests, they stimulated the immune system with stronger and more specific bacteria-killing activity than the best antibiotics available today. This includes human samples for all types of antibiotic-resistant bacteria including MRSA and E. coli.
In experiments on mice, they also performed better than traditional antibiotics. All compounds were also shown to be non-toxic to human cells. First author, Dr Kumar Singh, a member of Dr Dotiwala’s lab, said: “Immune activation represents the second line of attack of the DAIA strategy.
There are many concerns that the world is entering a “post-antibiotic” era. It can leave many common infections untreatable and makes many of the staples of modern medicine – including surgery, chemotherapy and organ transplant – impossible.
Dotiwala adds: “We believe this innovative strategy by DAIA could represent a potential turning point in the world’s battle against AMR, creating synergy between direct killing capabilities of antibiotics and the natural strength of the immune system.
The study was published in the journal nature.
SWNS writer Mark Waghorn contributed to this report.
https://kfor.com/news/potential-landmark-new-class-of-antibiotics-could-destroy-hospital-superbugs/ ‘Potential turning point’: New antibiotic can kill hospital superbugs